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Background: Linear polyethylenimine (LPEI) is considered as a desirable gene in vivo delivery system, but whether
it could deliver the specific siRNA targeted EGFR to the tumor site to inhibit the growth of NSCLC xenograft in
nude mice still needs to be examined.
Methods: In this study, LPEI/siRNA was made into a complex and SPC-A1-xenografted mice model was established.
Then, stable LPEI/siRNA-EGFR complexes were intraperitoneally administrated. Afterwards, tumor growth was
measured every 3 days. At the end of the experiment, tumor volume was calculated, and tumors were weighed,
and examined for EGFR expression, proliferation, and apoptosis evaluations. By using blood samples, toxicity tests
including aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea and creatinine (Cr) were measured
for liver and renal function evaluation. Serum concentrations of TNF-α and IFN-γ were also examined.
Results: Our results demonstrated that LPEI/siRNA-EGFR complexes could downregulate EGFR expression in SPC-A1
xenografted tumor upon single i.p. injection. LPEI/siRNA-EGFR complexes inhibited tumor growth and did not
induce organ toxicity in SPC-A1-xenografted mice. At the end of the experiment no significant IFN-α increase was
detected in LPEI/siRNA complexes or glucose-treated groups.
Conclusions: The novel modality of siRNA-based therapy targeting EGFR may be of great potential in NSCLC treatment.
Keywords: RNA interference, Small interfering RNA, Epidermal growth factor receptor, Linear-polyethylenimine, Non
small cell lung cancer, Intraperitoneal injectionBackground
Non-small-cell lung cancer (NSCLC) is a major global
health problem and is the leading cause of cancer death
worldwide [1]. Currently, non-specific and non-selective
treatment with cytotoxic chemotherapy results in only a
modest increase in survival, but at the cost of significant
toxicity. This underscores the need for novel agents with
improved efficacy and safety profiles [2-5]. Among those,
the epidermal growth factor receptor (EGFR) is one of
the most important targets in NSCLC therapy [6]. The
currently available agents targeting EGFR in NSCLC* Correspondence: bai.chunxue@zs-hospital.sh.cn
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in any medium, provided the original work is ptreatment are two small molecular tyrosine kinase inhi-
bitors (TKIs), including gefitinib and erlotinib. A phase
III, open-label study demonstrated the presence in the
tumor of a mutation of the EGFR gene is a strong pre-
dictor of a better outcome with gefitinib [7]. Even more,
EGFR-TKI was recently recommended to be the first-line
therapy in EGFR-mutation positive patients with NSCLC.
Unfortunately, the responsive rate to the EGFR-TKIs is
low for reasons such as primary or secondary resistance
[8-12]. Thus, no adequate treatment options currently
exist for EGFR-tumor-driven patients who have experi-
enced EGFR-TKIs and chemotherapy failure [13].
In recent years, RNA interference (RNAi) has drawn
attention in therapeutic studies of cancer [14-16]. It was
discovered to be a process of post-transcriptional gene
silencing, which induces degradation of a homologousn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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sequence-specific manner [17,18]. Due to this property,
siRNA sequences have been designed for many target
mRNAs. For example, the target of interest could be a
mutated protein, as in the case of NSCLC patients resist-
ant to EGFR-TKIs. Additionally, conventional small
molecule drug discovery involves complicated screening
and random modifications, thus leading to new com-
pounds. However, to design a therapeutic siRNA
requires only knowledge of the target gene’s sequence,
and thus can be chemically synthesized at relatively low
cost. In this regard, the novel therapeutic modality of
siRNA-based gene silencing may have advantages over
drugs currently on the market.
However, for further in vivo application, the negative
charge and chemical degradability of siRNA under physio-
logically relevant conditions make its delivery a major
challenge. Viral vectors have high in vitro gene transfer
efficiency, but their limited carrying ability of genetic
material and severe safety risks induced by their immuno-
genicity and oncogenic potentials deter broad use in
humans [19]. Recently, non-viral vectors have been inves-
tigated for their ease of preparation, purification, and
chemical modification, as well as their stability. Among
these lipoplexes have shown significant toxicities. In con-
trast, the cationic polymers, polyethylenimine (PEIs), are
regarded as the most efficient and versatile non-viral vec-
tors [20]. Of these, linear PEI (LPEI) has been widely
employed in gene transfer into varied organs [21], such as
lung, brain, retina, pancreas, and bladder tumors [22-25].
Clinical trials for the treatment of bladder cancer and
human immunodeficiency virus (HIV) infection have been
underway, using LPEI-mediated plasmid DNA delivery
[26]. Moreover, this delivery system has recently been suc-
cessfully applied in siRNA delivery in vivo [27]. The posi-
tive charges of LPEI are felt to allow efficient interaction
with siRNA, forming complexes which bind onto cell
membranes and undergo endocytosis. Then, LPEI uses the
so-called “proton sponge” effect to enhance endosomal re-
lease of the polyplexes and bringing out the RNAi to
plasma [28].
Based on the above, The ultimate aim of our study
was to discover novel siRNA-based therapy targeting
EGFR in human NSCLC. First, we tested whether LPEI
could efficiently deliver EGFR-specific siRNA to the
tumor site, leading to an antitumor effect in human
NSCLC cell xenografts, when administered by intraperi-
toneal injection. Then toxicity and immunogenic reac-
tions after systemic release also evaluated for safety.
Methods
Cell lines and animals
SPC-A1, a well-characterized human lung adenocarcin-
oma cell (HLAC) line, was obtained from Shanghai Celland Biology Institute. Cells were maintained in RPMI
1640 medium (Gibco, USA) supplemented with 10%
bovine serum (Gibco, USA), 2mmol/L L-glutamine and
antibiotics (100U/mL penicillin and 100 μg/mL strepto-
mycin) in a humidified atmosphere of 5% CO2 at 37. The
8-week-old male BALB/C nude and immunocompetent
mice (body weight 20±2g) bought from Chinese Academy
of Science, were kept in filter-topped cages with standard
rodent chow and water available ad libitum, and a 12
hours light/dark cycle. Those nude mice were randomly
allocated into different groups and there were 6 mice
for each group. All animal protocols were approved by
the Ethical Committee on Animal Experiments of the
University of Fudan Animal Care Committee, Shanghai,
China. All efforts were made to minimize suffering.
siRNAs




50-AUUUCUCAUGGGCAG CUCCdTdT-30), designed as
previous description [29], were chemically synthesized and
annealed by GenePharma (Shanghai, China). Aqueous
siRNA (20 μmol/L and 200 μmol/L) were subpackaged and
stored at −80.
LPEI/siRNA complexes preparation and cell transfection
in vitro
Commercial low molecular weight (22 kDa) Linear-PEI
(jetPEITM), for in vitro DNA transfection, was bought
from PolyPlus-transfection (Illkirch, France) and stored
at −80. LPEI consisted of 7.5 mmol/L of NH4
+. LPEI/
siRNA was made into a complex. In brief, 5 μl siRNA
was dissolved in 100 μl of 10 mmol/L HEPES-150
mmol/L NaCl, pH 7.4, and incubated for 10 minutes.
LPEI (2.5 μl) was dissolved in 100 μl of the same buffer
and, after 10 minutes, was pipetted into the siRNA solu-
tion. This gave a net molar excess of ionizable nitrogen
of LPEI to phosphate of siRNA (N/P) at a ratio of 5 as
suggested for DNA by the manufacturer. Corresponding
LPEI/siRNA complexes were constructed at N/P ratios
of 3, 5 and 10. The total 200 μl mixture was vortexed and
incubated at room temperature for 20 minutes to form a
stable LPEI/siRNA-EGFR complex, and then dropped
slowly into each well of 6-well plates. Serum-free DMEM
was supplemented to a final volume of 2 mL, and 4 hours
later replaced with RPMI 1640 medium.
Cells were harvested 24 hours after transfection. Total
RNA was isolated from cells using TRIZOL Reagent
(Invitrogen, USA), purified as recommended by the
manufacturer, and then reverse-transcribed with M-
MLV Reverse Transcriptase Kit (Promega, USA) follow-
ing the manufacturer’s instructions. Real-time RT-PCR
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Mix (TOYOBO, Japan) and amplified with a Roter-Gene
3000 Amplification System (Corbett Research, Australia).
Primer sequences used for EGFR (forward 50-ACCGT
GCCCTGATGGATGA-30, reverse 50-CCACGGTGGAAT
TGTT GCTG-30) and β-actin (forward 50-ATGACCCAG
ATCATGTTTGAGACC-30, reverse 50-GGAGGGCATA
CCCCTCGTAGA-30) were designed and synthesized by
Sangon Co. (Shanghai). All samples’ EGFR mRNA expres-
sion levels were normalized by β-actin amplification.
Flow cytometry assays were performed at 48 hours
after transfection for the EGFR numbers scoring. After
trypsinizing from plates, cells were washed twice with
1×PBS, then incubated with 20 μl of R-PE-conjugated
mouse anti-human EGFR monoclonal antibody (BD
Biosciences, USA) for 15 min in the dark at room
temperature. Afterwards, cells received the same wash-
ing process and fixed in 0.5 mL of 4% paraformaldehyde.
The EGFR numbers were analyzed on a Becton Dickinson
FACScan flow cytometry with excitation and emission set-
tings of 488 nm and 575 nm, respectively. To determine
the change of EGFR numbers in SPC-A1 cells, we used
positive cell percentage × mean intensity to evaluate the
intensity of fluorescence.
For specificity evaluation, non-specific siRNA-NEG was
complexed by LPEI at corresponding N/P ratios and
thereafter transfered into SPC-A1 cells. Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) complexed siRNA-
EGFR transfecting group was set as a positive control. The
non-treatment group was taken as a blank control. EGFR
mRNA or protein expression levels were normalized by
setting the amount of blank control at 1.0.
Size and zeta-potential measurements
Dynamic light scattering (DLS) was employed to deter-
mine hydrodynamic diameters of the complexes, and
laser Doppler anemometry (LDA) was utilized to meas-
ure their zeta potentials. LPEI complexed siRNA nano-
plex was prepared as above. Plasmid DNA (pShNEG)
provided by pSilencerTM 2.1-U6 neo kit (Ambion, Inc.,
Austin, TX, USA) was complexed with LPEI at the same
N/P ratio of 5 as the manufacturer’s instructions. When
the LPEI/siRNA and LPEI/DNA complexes were formed,
their mean particle size and zeta-potential distribution
were measured using a Zeta potential/particle Sizer
NicompTM 380 ZLS (PSS Nicomp particle size system,
USA). Position and attenuator were optimized by the de-
vice. Measurements were conducted in quadruplicates.
LPEI/siRNA complexes transfection in vivo by intraperitoneal
(i.p.)injection
SPC-A1 cell suspension was prepared and inoculated
subcutaneously into flanks of nude mice (1×107 cells
/100 μl per site), (n = 6). As grown up tumors wereremoved and divided into uniform masses of 1 mm × 1
mm, and implanted subcutaneously into the right flank
of the untreated mice. When tumors reached 6 mm × 6
mm, the SPC-A1-xenografted mice model was success-
fully established and i.p. treatment started.
For i.p. injection, the in vivo-jetPEITM transfection
reagent (optimized cationic linear PEI-based transfection
reagent for in vivo experiments), also from Polyplus-
transfection (Illkirch, France), was used, which provided
as a ready-to-use solution at 150 mM nitrogen concen-
tration and less than 0.1EU/mL endotoxin. SiRNA-EGFR
(3 μl, 200 μmol/L) and LPEI (0.75μl) were dissolved in
250μl of 5% glucose solution (GS), respectively. The
latter was pipetted into the siRNA solution 10 minutes
later. After vortexing and incubating at room temperature
for 20 minutes, stable LPEI/siRNA-EGFR complexes
under N/P ratio of 5 were formed in 5% GS at a final vol-
ume of 500μl. Afterwards, they were intraperitoneally
administrated to each mouse in 1h. At the same time, a
corresponding dose of LPEI complexed non-specific
siRNA-NEG or 5% GS were given to the other two groups
as controls.
In the experiment of discontinued administration, i.p.
injection was started (day 0) when tumors had reached 6
mm × 6 mm, and repeated 2~3 times per week until the
22nd day, 24 h after the last injection. Tumor growth
was measured every 3 days using a digital caliper by
an observer blinded to treatment allocation. Tumor vol-
ume was calculated (0.52× longest diameter × shortest
diameter2) [30]. At the end of the experiment, tumors
were harvested, weighed, and examined for EGFR ex-
pression, proliferation, and apoptosis evaluations. No
deaths of nude mice was observed during the experi-
ment process.
Western blot analysis
EGFR expression in tumor samples was detected by
western blot. Tissue was homogenized, centrifuged, and
supernatants collected. Equivalent amounts of extracted
protein (50 mg) were mixed with sample buffer contain-
ing 5% 2-mercaptoethanol, boiled, cooled, and loaded in
each lane of a 7.5% polyacrylamide gel. Electrophoresis
was performed at a constant voltage of 80V and, subse-
quently, proteins were transferred to a PVDF membrane.
The membrane was blocked overnight with 3% gelatin
in Tris-buffered saline (TBS). Subsequently, membranes
were incubated with mouse anti-EGFR primary antibody
(1:1000, BD Biosciences, USA) at 4°C overnight, and
after washing twice in TBST, with peroxidase-conjugated
goat anti-mouse IgG (Santa Cruz biotechnology, Inc.,
Santa Cruz, CA, USA) at room temperature for 1 hour.
GAPDH was used as an internal control. Protein blots
were visualized with chemiluminescence reagent ECL
(Amersham, Freiburg, Germany). Membranes were washed
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quantified by scanning densitometry.
Immunohistochemisty and terminal deoxynucleotidyl
Transferase Biotin-dUTP Nick End Labelling (TUNEL) assay
Tumors were fixed in 4% paraformaldehyde and embed-
ded in paraffin. IHC detection of EGFR and proliferating
cell nuclear antigen (PCNA) were performed in 3μm
histological sections. Briefly, sections were immersed in
xylene, 95% alcohol, and 80% alcohol for 10 min, respect-
ively, and washed with PBS (pH 7.4) for three times after
each immersion. After protein denature, using microwave
and non-specific biding blocking with normal goat serum
for 20 min at RT, sections were incubated with primary
antibodies against EGFR or PCNA (both diluted to 1:100,
Maixin-Bio, China) overnight at 4°C. Sections were
washed with PBS and incubated with goat anti-mouse sec-
ondary antibody (Cell Signaling) at a 1:100 dilution for 20
min at 37°C. Sections were again washed with PBS and
incubated for 20 min with SABC. After again being
washed with PBS, sections were incubated with 3, 3-di-
aminobenzidine (DAB) for 3~5 min, and the reaction
stopped by washing in PBS. Microscopically, brown parti-
cles appeared within cells, indicating positive expression
of the protein molecules assessed. Five consecutive high-
power fields (×200) were examined in each of specimen
under a light microscope (Carl Zeiss, Germany) in a
blinded fashion. The proliferation index was calculated
according to the following formula: number of PCNA
positive cells/ total cell count × 100%.
LPEI/siRNA complexes inducing cell apoptosis was
assessed by measuring DNA strand breaks using an in situ
cell death detection kit (Roche Applied Science, Indian-
apolis, IN, USA) based on TUNEL staining. Tissue slides
were fixed in 4% paraformaldehyde for 10 minutes, fol-
lowed by washing in phosphate buffered saline (PBS) and
blocking in 3% H2O2 methanol for 10 min. After perme-
abilisation in a solution containing 0.1% Triton X-100 and
0.1% sodium citrate, tissues were labelled with 25 ml of
TUNEL reaction mixture containing a 1:2 dilution of en-
zyme for 2 hours at 37°C in a humidified chamber. Signals
were then converted into HRP using antifluorescein anti-
body and visualized by 3,30diaminobenzidine coloration
(Roche Applied Science, Indianapolis, Indiana, USA) as
recommended by the manufacturer. Tissues were counter-
stained with methylgreen and TUNEL-positive cells were
counted in five randomly selected × 200 high-power fields
under microscopy. The apoptosis index was calculated
according to the following formula: number of apoptotic
cells/total number of nucleated cells × 100%.
Blood biochemical analysis
At the endpoint of the above experiment, all blood sam-
ples were collected for toxicity testing. By retro-orbitalpuncture, blood was collected into heparinized tubes.
Within 1 h, samples were centrifuged at 5000 × g for 10
min. The plasma was taken for biochemical parameters
analysis, carried out with an automatic analyzer (HITACHI
7020, JAPAN). Liver enzymes, including aspartate amino-
transferase (AST), and alanine aminotransferase (ALT),
were measured. Urea and creatinine (Cr) were also mea-
sured for renal function evaluation.
Immunogenicitiy assay
SiRNA-EGFR or non-specific siRNA-NEG (0.6 nmol),
both complexed with LPEI in 5% glucose solution, were
administrated by i.p. injection to 8-week-old male
BALB/C nude or immunocompetent mouse, and 500 μl
of 5% glucose solution was given as a negative control.
After 2 days, the injection was repeated at 6 h before the
end of the experiment. As a positive control based on a
previous study, 40 μg of lipopolysaccharide (LPS, Sigma,
St. Louis, MO) in 500 μl of phosphate-buffered saline
(PBS) was intraperitoneally administrated to immuno-
competent mouse and the experiment terminated after 2
h. Mice blood was taken by retro-orbital puncture and
allowed to clot overnight at 4°C. Samples were centri-
fuged at 5000 × g for 10 min, and the supernatants col-
lected. Serum concentrations of TNF-α and IFN-γ were
determined by enzyme-linked immunosorbent assay
(ELISA) kits according to manufacturer’s instructions
(R&D Systems, Minneapolis, MN, USA). The amount of
cytokine was determined on 100 μl of × 5 diluted serum,
loaded in duplicate.
Statistical analysis
Data were presented as the means ± standard deviation.
Statistical differences among multiple groups were calcu-
lated by one-way analysis of variance (ANOVA). If a
ANOVA was statistically significant, an unpaired two-
tailed Student’s t-test was used for between-group com-
parisons. P values of less than 0.05 were considered
statistically significant.
Results
In vitro optimizing of LPEI/siRNA-EGFR complexes
We first performed an in vitro experiment to test
whether LPEI could deliver unmodified siRNA efficiently
into human lung cancer cells and exert a specific gene
silencing effect. The N/P ratio, which indicates quotient
of the nitrogen atoms of LPEI to siRNA phosphates
in the complexes, will determine particle size and zeta-
potential, thus influencing the efficiency of siRNA deliv-
ery. LPEI/siRNA-EGFR complexes were prepared at
various N/P ratios (= 3, 5, 10, respectively) and their
silencing efficiencies were evaluated in the SPC-A1 cell
line, previously proven to have a high level of EGFR
expression [31]. Compared to non-specific LEPI/siRNA-
Table 1 Characteristics of LPEI-complexed nucleic acid
under N/P ratio of 5
Complexes type Mean particle size (nm) Zeta-potential (mV)
LPEI/siRNA 87.13±11.11 6.22±1.63
LPEI/DNA 148.93±9.71 7.44±0.58
All data were presented as means ± s.d of numbers obtained from 6 animals
in each group.
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LPEI-complexed siRNA-EGFR resulted in target gene
expression down-regulation under each N/P ratio, with
all differences being significant. Under an N/P ratio of 5,
76.42% of down-regulation in EGFR mRNA was obtained
at 24h after LPEI/siRNA-EGFR transfection (Figure 1A).
An EGFR protein reduction of 63.53% was also confirmed
by flow cytometry assays at 48h following treatment
(Figure 1B). These results were similar to those of the
Lipofectamine/siRNA-EGFR -transfected group. The lower
efficiency at N/P ratio of 3 may have been due to an insuf-
ficient complexation of siRNA by LPEI (data not shown).
Additionally, because the dose increase of LPEI under N/P
ratio of 10 did not lead to a higher silencing efficacy, the
optimal N/P ratio was considered as 5 for LPEI-vectored
siRNA-EGFR delivery during the in vitro and further
in vivo studies.
To explain the optimal silencing efficiency produced
by LPEI-complexed siRNA, the mean particle size and
zeta-potential distribution were determined. Further-
more, considering that jetPEI was introduced previously
as a DNA plasmid transfection reagent, these parameters
were compared with LPEI/plasmid DNA complexes
using the same N/P ratio. As displayed in Table 1, the
electrostatic interactions between LPEI and siRNA
resulted in formation of complexes with average particle
size distribution of ~100 nm, while LPEI/DNA com-
plexes showed ~2-fold increase in size, revealing that
LPEI/siRNA complexes were more compact as com-
pared with LPEI/DNA complexes. Similar lower positive
surface potential were detected in both complexes.
LPEI/siRNA-EGFR complexes downregulate EGFR expression
in SPC-A1 xenografted tumor upon single i.p. injection
The ultimate goal of our study was to explore the thera-
peutic use of EGFR-specific siRNA through systemicFigure 1 In vitro comparison of transfection efficiencies. In vitro compa
ratios (black panels), LPEI/siRNA-NEG (grey panels), and Lipofectamine/siRNA-EG
plates at 3 × 105 cells/well and, at ~50% confluency, transfection was performe
expression of EGFR mRNA by real-time RT-PCR analysis, (B) and after 48 hours
d. of numbers obtained from 6 animals in each group. All the results are show
compared with respective LPEI/siRNA-NEG groups. ‡ P<0.05 when compared wapplication. Indeed, it has been known that many vectors
have failed with in vivo gene delivery in spite of good
transfection abilities in vitro. Therefore, we examined
whether LPEI-complexed siRNA-EGFR under N/P ratio
of 5 could also induce efficient target gene silencing upon
a single i.p. injection in vivo. SPC-A1-xenografted mice
were randomly divided into three groups. As tumors
reached 6 mm×6 mm, each mouse was intraperitoneally
injected with 0.6 nmol of siRNA-EGFR complexed with
LPEI. Corresponding doses of LPEI/siRNA-NEG or 5%
GS were administrated as control groups. Twenty-four
hours later, the mice were killed and their tumors pro-
cessed for RNA extraction. Quantitative real-time PCR
analysis (Figure 2A) revealed a 49% reduction of EGFR
mRNA content of tumors treated with LPEI/siRNA-EGFR
complexes in comparison with the non-specific LPEI/
siRNA-NEG control, the results showing no significant
difference with GS control group. Consistently, at 48h
after LPEI/siRNA-EGFR complexes injection, tumor west-
ern blot analysis (Figure 2B) showed significant decrease
(51%) in EGFR protein expression as compared with the
non-specific control group. IHC examination (Figure 2C)
confirmed a marked EGFR silencing efficiency of the
LPEI/siRNA-EGFR complexes. These results suggested
that EGFR-specific siRNA complexed with LPEI could ef-
ficiently reduce EGFR expression at both mRNA and pro-
tein levels in SPC-A1-xenografted tumors, with no non-
specific RNAi effect being observed.rison of transfection efficiencies of LPEI/siRNA-EGFR under various N/P
FR (white panel) transfected groups. SPC-A1 cells were seeded into 6-well
d as indicated. Cells were harvested (A) after 24 hours for quantitative
for EGFR protein by flow cytometry assays. Data are expressed as means±s.
n as the mean±standard error of the mean (SEM). * P<0.05 when
ith LPEI/siRNA-EGFR group at different N/P ratios.
Figure 2 Reduction of EGFR expression in SPC-A1 xenografts upon LPEI/siRNA-EGFR complexes injection, compared with control
groups. (A) EGFR mRNA quantitative evaluation by real-time RT-PCR at 24 hours after injection. (B) Western Blot analysis, and (C) IHC staining of
EGFR protein determination at 48 hours after injection. EGFR seen as brown stain, with magnification ×200 (upper) and ×400 (lower)(n = 6).All the
results are shown as the mean±standard error of numbers obtained from 6 animals in each group. *P < 0.05.
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following repeated i.p. administration
Previously we demonstrated that stable downregulation
of EGFR expression by vector-based shRNA significantly
inhibited NSCLC cells proliferation [31]. Therefore, we
used the athymic nude mouse model to test if repeated
systemic administration of LPEI-complexed and EGFR-
specific siRNA could result in growth inhibition of SPC-
A1-xenografted tumors. Mice were grouped and treated
as described above. As shown in Figure 3A, tumors in
mice treated with LPEI-complexed non-specific siRNA
grew similar to those of GS-treated mice and followed
for 2 weeks. Nonetheless, there was no significance dif-
ference. However, treatment with EGFR-specific siRNA
vectored by LPEI induced significant tumor growthinhibition. Differences reached statistical significance at
day 10, and tumor weight reduction at day 22 was
almost 50% (Figure 3B). Also, tumor IHC revealed a
marked downregulation of EGFR protein expression in
the LPEI/siRNA-EGFR-treated group (Figure 3C), and,
as shown by western blot analysis, inhibitory efficiency
was 55% (Figure 3D).
To identify tumor proliferation and apoptosis following
i.p. injections with LPEI-complexed EGFR specific siRNA,
we also examined PCNA expression and apoptosis-
induced DNA fragmentation in mice xenografts. As
shown (Figure 4A), in the LPEI/siRNA-EGFR-treated
group, PCNA positive staining was reduced, while
TUNEL-positive cell counts were significantly higher than
in the other two groups (Figure 4B). Comparisons
Figure 3 Growth inhibition of SPC-A1 xenografts. Followed by systemic treatment with LPEI-complexed EGFR-specific siRNA, the growth of
SPC-A1 xenografts has been inhibited because of decreased EGFR expression. Subcutaneous xenografts generated as described above. (A)
Intraperitoneal injection performed every 3 days with 0.6 nmol LPEI/siRNA-EGFR (open circles), LPEI/siRNA-NEG (closed circles), and 5% GS
(triangles), respectively. Tumor volumes recorded every 3 days. Data expressed as mean of six mice in each group. (B) Tumor weight comparisons
between three groups at endpoint of experiment. (C) IHC and (D) Western blot analysis for EGFR protein levels. All the results are shown as the
mean±standard error of numbers obtained from 6 animals in each group. *P < 0.05; **P < 0.01.
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proliferation index (Figure 4C), as well as a >twofold in-
crement in the apoptosis index (Figure 4D) under LPEI-
complexed EGFR-specific siRNA treatment. In contrast,
no significant difference was found in cell proliferation or
apoptosis between LPEI/siRNA-NEG and GS treated
groups. These results provide evidence that the observed
inhibitory effect on tumor growth was based on specific
EGFR down-regulation, acting through modulations of
cell proliferation and apoptosis.
Toxicity
To determine whether following repeated systemic ad-
ministration with the LPEI/siRNA-EGFR complexes
there could be organ toxicity, mice blood levels of ALT
and AST, urea and creatinine (Cr) were measured. As
shown in Table 2, there was no evidence of increased liver
toxicity or significance renal toxicity. In addition, micro-
scopically, there was neither necrosis nor inflammatorycell infiltration of the heart, liver, lungs, or kidneys (data
not shown). These results suggest that the therapy of
repeated i.p. administration with 0.6 nmol EGFR-specific
siRNA vectored by LPEI does not induce organ toxicity in
SPC-A1-xenografted mice.
Immunogenicity of LPEI/siRNA-EGFR
To evaluate the immunogenic reaction following i.p. in-
jection of EGFR-specific siRNA mediated by LPEI, we
tested serum levels of pro-inflammatory cytokines, in-
cluding IFN-α and TNF-α, which have been reported to
be increased after siRNA delivered by lipids in vivo [32].
Preparation and dose of the LPEI/siRNA complexes
were the same as in the above tumor growth inhibition
experiment. As indicated in Figure 5A, after the last treat-
ment with 0.6 nmol of LPEI-complexed siRNAs, TNF-α
production increases were induced in neither nude nor
immunocompetent mice compared with the negative con-
trol group. On the other hand, LPS treatment led to a
Figure 4 After repeated i.p. administration, tumor PCNA protein expression detected by IHC. (A) and apoptosis examined by TUNEL assay
(B). Quantitative analysis data revealed 37% reduce in cell proliferation index in LPEI/siRNA-EGFR group compared with other two groups (C), and
more than twofold increase in apoptosis index under LPEI /siRNA-EGFR treatment (D). All the results are shown as the mean±standard error of
numbers obtained from 6 animals in each group. *P < 0.05.
Zhang et al. Translational Respiratory Medicine 2013, 1:2 Page 8 of 11
http://www.transrespmed.com/content/1/1/2significant increase of serum TNF-α level in the positive
control group, as expected. Similarly, at the end of the
experiment no significant IFN-α increase was detected
in LPEI/siRNA complexes or glucose-treated groups
(Figure 5B).
Discussion
The success of siRNA-based strategies in vivo relies on a
delivery system which can efficiently protect and carryTable 2 Liver and renal function evaluation following
repeated i.p. injection in tumor-xenografted mice




5% GS 58.33±11.38 188.17±39.75 9.73±0.97 48.43±2.48
LPEI/siRNA-NEG 55.00±11.03 184.67±62.24 10.45±0.68 47.70±3.61
LPEI/siRNA-EGFR 53.83±13.47 178.33±53.41 10.35±1.04 46.87±7.55
Data presented as means±s.d. of numbers obtained from 6 animals in each group.siRNA across various intracellular and extracelluar
barriers into target cells in order to result in sequence-
specific mRNA degradation [33]. In light of the poor
clinical safety of viral vectors, linear polyethylenimine
(LPEI) has emerged as a potent candidate because of its
versatility and comparatively high gene transfection effi-
ciency [34]. Because of its potential for DNA delivery,
we used a commercial low molecular weight (22 kDa)
linear PEI. The in vitro data demonstrated that, upon
delivery of LPEI, a significant EGFR protein down-
regulation was achieved in SPC-A1 cells by transfection
of an EGFR-specific siRNA. Its efficiency was compar-
able to Lipofectamine 2000, a commonly used cationic
liposome-based transfection reagent. As reported by
many studies [20,35], this can be explained with the prop-
erty that cationic LPEI can potently compact negatively
charged siRNAs into stable complexes with proper posi-
tive surface potential. This will facilitate their interaction
Figure 5 Serum levels of inflammatory factors. ELISA assays showing changes in serum levels of IFN-α (A) and TNF-α (B). Both cytokines
clearly increased after LPS administration, while no significant change was observed in LPEI/siRNA-EGFR, LPEI/siRNA-NEG or GS-administrated
groups. All the results are shown as the mean±standard error of the mean. *P < 0.05.
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resulting particle size of less than 100 nm is suitable for
endocytosis. This also enhances the complexes’ delivery
into cells, eliciting specific RNAi effects [36]. In one study,
Urban et al. found that i.p. injection of LPEI-complexed
siRNAs (0.8 μg) targeting the c-erbB2/neu (HER-2) recep-
tor resulted in a marked reduction of ovary tumor xeno-
graft growth. [37] Grzelinski used LPEI-complexed siRNA
targeting secreted growth factor pleiotrophin (PTN) to
treat U87 glioblastoma subcutaneous xenograft-bearing
mice As a result, intact siRNA was successfully delivered
and a ~40% inhibition of tumor growth was observed over
3 weeks. [27] Furtherly, in the orthotopic glioblastoma
mouse model, a low dose (0.2 μg) of LPEI-complexed
PTN siRNA was injected into the central nervous system,
also exerting an antitumor effect. Similarly, in our present
experiment, upon intraperitoneal injection and complex-
ing of LPEI EGFR-specific siRNA (0.8 μg) induced a
marked down-regulation of EGFR expression in NSCLC
xenografts, also resulting in significant tumor growth in-
hibition by repeated treatments noted after 3 weeks. There
was no statistical difference between the LPEI-complexed
non-EGFR-specific siRNA and glucose-treated groups,
demonstrating the specificity of target mRNA degradation
in mechanism, and no antitumor effect from the non-viral
vector was observed. ,Moreover, there are some studies,
which reported high dose of naked siRNA delivery in mice
by high-pressure tail injections. However, this method was
considered to be too toxic and not compatible with clin-
ical application [16]. In comparison, LPEI can carry a
lower dose of siRNA to effectively exert an antitumor
effect in vivo [38].
One key factor for successful RNAi-based therapy is to
choose the right target genes. With increasing knowledge
of cancer cell signaling pathways, inhibition of critical sig-
nal transducers involved in proliferation or survival is apromising direction for developing siRNA-based cancer
therapeutics [18]. EGFR is a glycoprotein with a molecular
weight of 170,000 to 180,000, and an intrinsic tyrosine-
specific protein kinase, stimulated upon epidermal growth
factor (EGF) binding. A previous study[31] indicated that
significant and specific down-regulation of EGFR expres-
sion by vector-based short hairpin RNA (shRNA) can in-
hibit human lung adenocarcinoma cell (A549 and SPC-
A1) growth, induce cell apoptosis, and subsequently in-
crease sensitivity to cisplatin, doxorubicin, and paclitaxel
by about 4- to 7-fold in these two HLAC cell lines, re-
spectively. Based on these results, the present study has
taken a giant step forward by successfully in vivo applying
the EGFR-target siRNA complexed with LPEI, eliciting a
marked antitumor effect through specific EGFR down-
regulation.
Given that it is crucial to identify potential side effects
induced by this siRNA-based therapeutic system, toxicity
and production of pro-inflammatory cytokines after
siRNA-based therapy were examined. As shown in the
repeated-injection experiment, no adverse effect on hep-
atic or renal function was observed from LPEI-complexed
siRNA-EGFR treatment. Microscopic examinations of the
heart, liver, kidneys and lungs also revealed no detectable
damage. As for immunogenicity, treatment with EGFR-
specific or non-specific siRNA (0.8 μg, 0.4 mg/Kg body
weight) complexed with LPEI did not change serum TNF-
α or IFN-α levels compared with glucose-treated mice,
which as an indication of a severe immune response, can
be triggered by siRNA over-dosage, an improper sequence
design, or certain delivery vectors and induce injuries
in vitro or in vivo [32,39]. Similarly, Grzenlinski found no
obvious production of pro-inflammatory cytokines in a
glioblastoma mouse model [27], while Bonnet et al. [40]
revealed no induction of inflammation or liver damage
was observed after i.v. injection of the formulation.
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for clinical application.
As a new technology, siRNA-based therapy has rapidly
moved into the clinic. Vascular endothelial growth factor
(VEGF)-targeted siRNA, bevasiranib, although did not
show significant response in the phase III trial, is the
first trying towarding siRNA-based tumor targeted
therapy. . As, ALN-RSV01, against the mRNA of the
respiratory syncytial virus (RSV) nucleocapsid (N) pro-
tein, is the first antiviral siRNA to enter clinical trials
[41]. Concerning system administration, the first phase I
clinical trial of tumor-targeted delivery of siRNA was
started in 2008 [42,43].
The present study has demonstrated that a LPEI-
complexed EGFR-specific siRNA delivery system can
efficiently and effectively inhibit EGFR expression in
SPC-A1 cells in vitro. This is the first report of its effect-
ive therapeutic application with intraperitoneal injection
in a preclinical NSCLC cell xenograft model, with good
biological safety.
Conclusions
Given these results, the novel modality of EGFR-target
siRNA-based therapy may have promise in human NSCLC
patients.
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